GIP/GLP-1 Dual Agonists Billing & Prior-Auth Playbook

Which product matches which diagnosis?

Tirzepatide activates both the GIP receptor and the GLP-1 receptor, and its FDA label describes it as a dual agonist rather than a pure GLP-1 agonist [1]. Two brand labels exist: Mounjaro for type 2 diabetes and Zepbound for weight reduction and obstructive sleep apnea [1][2].

Zepbound is labeled for weight reduction; Mounjaro is labeled for type 2 diabetes and has no weight-management indication [1][2]. Other FDA-approved weight-management options include Wegovy injection and tablets, Saxenda and generic liraglutide for weight management, and Foundayo [3][4][5]. Foundayo is an oral GLP-1 receptor agonist, not a dual agonist, and its label has no diabetes indication [5]. Semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide and orforglipron are GLP-1 receptor agonists, not dual GIP/GLP-1 agonists [3][4][5][7][8][9]. Diabetes-only labels include Ozempic, Rybelsus, Victoza, Trulicity, Byetta, Mounjaro, Soliqua and Xultophy [3][4][1][5].

Label points that come up in a coverage review

The Wegovy, Saxenda, Zepbound and Foundayo labels do not recommend use with another GLP-1 receptor agonist [3][4][1][5]. The boxed-warning products are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 [3][5]. Labeled class warnings include acute pancreatitis, severe gastrointestinal reactions, acute kidney injury from volume depletion and acute gallbladder disease [3][5]. Billing codes, payer step-therapy criteria and appeal deadlines are set by the plan or payer, not by FDA product labeling.

Compounded tirzepatide

FDA says compounded tirzepatide is not FDA approved and is not reviewed for safety, effectiveness or quality [6]. On 2026-04-30 FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the list of bulk substances outsourcing facilities may compound with, finding no clinical need; comments were due 2026-06-29 and no final decision had been made [10].